prikaz prve stranice dokumenta Nuspojave oralnih antikoagulantnih lijekova
  Download
PDF 628.67 KB
Professional paper - Review paper
Nuspojave oralnih antikoagulantnih lijekova
Medicina Fluminensis, 51 (2015), 2; 267-275. urn:nbn:hr:184:443368
Starčević, Alma; Vukelić-Damijani, Nada; Balen, Sanja; Vlahović-Palčevski, Vera

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Starčević, A., Vukelić Damijani, N., Balen, S. & Vlahović Palčevski, V. (2015). Nuspojave oralnih antikoagulantnih lijekova. Medicina Fluminensis, 51. (2), 267-275. Retrieved from https://urn.nsk.hr/urn:nbn:hr:184:443368

Starčević, Alma, et al. "Nuspojave oralnih antikoagulantnih lijekova." Medicina Fluminensis, vol. 51, no. 2, 2015, pp. 267-275. https://urn.nsk.hr/urn:nbn:hr:184:443368

Starčević, Alma, Nada Vukelić Damijani, Sanja Balen and Vera Vlahović Palčevski. "Nuspojave oralnih antikoagulantnih lijekova." Medicina Fluminensis 51, no. 2 (2015): 267-275. https://urn.nsk.hr/urn:nbn:hr:184:443368

Starčević, A., et al. (2015) 'Nuspojave oralnih antikoagulantnih lijekova', Medicina Fluminensis, 51(2), pp. 267-275. Available at: https://urn.nsk.hr/urn:nbn:hr:184:443368 (Accessed 30 November 2024)

Starčević A, Vukelić Damijani N, Balen S, Vlahović Palčevski V. Nuspojave oralnih antikoagulantnih lijekova. Medicina Fluminensis [Internet]. 2015 June 01 [cited 2024 November 30];51(2):267-275. Available at: https://urn.nsk.hr/urn:nbn:hr:184:443368

A. Starčević, N. Vukelić Damijani, S. Balen and V. Vlahović Palčevski, "Nuspojave oralnih antikoagulantnih lijekova", Medicina Fluminensis, vol. 51, no. 2, pp. 267-275, June 2015. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:443368. [Accessed: 30 November 2024]

Metadata
Title (croatian)Nuspojave oralnih antikoagulantnih lijekova
Title (english)The side effects of new oral anticoagulants
AuthorAlma Starčević
AuthorNada Vukelić-Damijani
AuthorSanja Balen
MBZ: 236875
AuthorVera Vlahović-Palčevski
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Pharmacology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Clinical Pharmacology and Toxicology
Abstract (croatian)
Novi oralni antikoagulansi, izravni inhibitor trombina (dabigatran eteksilat) i inhibitori faktora Xa (rivaroksaban i apiksaban) pokazali su se jednakovrijedni ili superiorni u odnosu na varfarin u prevenciji ili liječenju venske tromboembolije. Ovaj kratki pregled opisuje mehanizam djelovanja, kliničku primjenu i nuspojave novih oralnih antikoagulansa. Kao i svi antikoagulansi, novi oralni antikoagulansi imaju povećan rizik za nastanak krvarenja. Za razli- ku od varfarina, novi oralni antikoagulansi predstavljaju klinički izazov zbog nedostatka speci- fičnog antidota i testova za mjerenje razine lijeka. Prilikom odabira antikoagulantne terapije liječnik mora primijeniti personalizirani pristup prema svakom pacijentu.
Abstract (english)
New oral anticoagulants (NOACs), direct thrombin inhibitor (dabigatran etexilat) and factor Xa inhibitors (rivaroxaban and apixaban) both show noninferiority or even superiority to warfarin in the prevention or treatment of venous thromboembolism. This brief review describes the mechanism of action, clinical use and side effects of new oral anticoagulants. Like all other anticoagulant drugs, the NOACs carry an increased risk of bleeding. Unlike warfarin, the NOACs represent a clinical challenge due to the lack of specific antidotes and tests for the measurement of drug levels. When choosing anticoagulant therapy, the physician must apply a personalized approach to each patient.
Keywords (croatian)
Keywords (english)
Languagecroatian
Publication typeProfessional paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleMedicina Fluminensis
Numberingvol. 51, no. 2, pp. 267-275
p-ISSN0025-7729
URN:NBNurn:nbn:hr:184:443368
Publication2015-06-01
Document URLhttp://hrcak.srce.hr/139472
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2017-04-25 10:47:10